Drug Profile
LiPlaCis companion diagnostic - Allarity Therapeutics
Alternative Names: iCIP; LiPlaCis DRP™; LiPlaCis DRP™ companion diagnosticLatest Information Update: 30 Nov 2020
Price :
$50
*
At a glance
- Originator Oncology Venture
- Developer Allarity Therapeutics; Oncology Venture A/S
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer
- Discontinued Prostate cancer
Most Recent Events
- 30 Nov 2020 Phase II clinical development in breast cancer is still ongoing (Oncology venture pipeline, November 2020)
- 07 Oct 2020 Oncology Venture A/S is now called Allarity Therapeutics
- 07 Jan 2020 Phase II clinical development in breast cancer is still ongoing (Oncology venture pipeline, January 2020)